Scotiabank lowered the firm’s price target on Myriad Genetics (MYGN) to $20 from $24 and keeps an Outperform rating on the shares. The firm believes Myriad Genetics continued efforts to strengthen its Oncology and Women’s Health businesses and its operating efficiency well-position the company to reaccelerate growth and further improve its profitability profile in 2026 and beyond, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges
- Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler
- Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley
- Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler
- Myriad Genetics price target lowered to $11 from $13 at BofA